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A B S T R A C T
Purpose: A new leucine-rich glioma-inactivated 1 gene (LGI1) mutation inducing an amino acid sequence
substitution was found in a Korean family with autosomal dominant lateral temporal lobe epilepsy
(ADLTE). We report the clinical features and characteristics of this newly identiﬁed LGI1 mutation.
Methods: Clinical data were collected from a large ADLTE family. All exons and ﬂanking regions of the
LGI1 gene were directly sequenced. 243 healthy controls were screened for the putative mutation. The
‘Sorting Tolerant From Intolerant’ algorithm was employed for the prediction of mutated LGI1 protein
stability. LGI1 protein secretion was conﬁrmed in vitro by immunoblotting assay.
Results: The main clinical characteristics included a young age at onset (mean, 12.4 years), diverse
phenotypic manifestations, the occurrence of generalized tonic–clonic seizures, and a favorable
prognosis. The genetic analysis detected a nonsynonymous single nucleotide polymorphism of
c.137G > T coding for p.C46F in the ﬁve affected family members. This variant was not found in the
normal control population and one unaffected family member. All the amino acids substituted for
cysteine at position 46 of the LGI1 protein were predicted to damage protein stability in in silico analysis.
Mutated C46F protein was retained within the cell at the immunoblotting assay.
Conclusion: We identiﬁed a new LGI1 mutation in a large Korean ADLTE family which appeared to be
involved in the development of epilepsy through suppressing LGI1 protein secretion.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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One of the most widely investigated gene in partial epilepsy is
the leucine-rich glioma-inactivated 1 (LGI1) gene. Partial epilepsy
with autosomal dominant inheritance and semiological features
consistent with lateral temporal lobe seizure has been reported as
autosomal dominant lateral temporal lobe epilepsy (ADLTE) or
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1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.10.001gene of ADLTE was localized to the long arm of chromosome 10 in
1995, and epilepsy related LGI1 mutation was discovered in
2002.1,2 In relatively small series, LGI1 mutations have been found
in about 50% of ADLTE families.3–5 On the other hand, a
collaborative study of the Commission of Genetics of the Italian
League Against Epilepsy reported that LGI1 mutations were found
only in 10 (30%) of 33 ADLTE families. Also, they demonstrated a
signiﬁcantly lower penetrance rate and relative disease risk in non-
LGI1-mutated families compared with LGI1-mutated pedigrees,
suggesting that a complex inheritance pattern may underlie a
proportion of these families.6 Sporadic lateral temporal lobe
epilepsy cases with ictal auditory manifestations have been
described as idiopathic partial epilepsy with auditory features
(IPEAF). De novo LGI1 mutations have also been identiﬁed in IPEAF,
and account for about 2% of sporadic cases with IPEAF.7,8 Twenty-
six LGI1 point mutations related to epilepsy have been reported to
date.9 Microdeletion of LGI1 was found in 2012.10vier Ltd. All rights reserved.
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identiﬁed a new LGI1 mutation. We report the phenotypes, genetic
features, and laboratory ﬁndings.
2. Methods
2.1. Subjects and data collection
A large Korean family comprising 52 members (excluding their
spouses) came to our attention by simultaneously encountering
affected family members in the epilepsy clinic of Severance
Hospital. Detailed history taking revealed autosomal dominant
inheritance of epilepsy within this family. After the approval of the
Institutional Review Board of our institution, six family members
[ﬁve affected members (III-15, IV-8, IV-9, IV-14, and IV-16), and
one healthy member (IV-18)] who signed informed consents were
interviewed and underwent genetic analysis. Data collection was
focused on seizure semiology, age at seizure onset, and treatment
outcomes. The routine scalp EEG recordings were available in six
patients. Brain magnetic resonance imagings (MRIs) were
reviewed.
2.2. Genetic analysis
We performed exon scanning of all LGI1 (NG_011832.1 from
NCBI database) coding exons and splice junction sites by direct
sequencing to identify variants in six family members. Addition-
ally, any putative mutation was screened in 243 Korean population
data from our database. Genomic DNA was extracted from the
peripheral whole blood using a nucleic acid isolation device,
QuickGene-mini80 (Fujiﬁlm, Japan). The PCR protocol has been
optimized for amplifying LGI1 based on UCSC In-Silico PCR (http://
genome.ucsc.edu/cgi-bin/hgPcr?command=start). The PCR pro-
ducts were puriﬁed using a MultiScreen384-PCR Filter Plate
(Milipore, USA). The puriﬁed products were then sequenced using
a BigDye Terminator Cycle Sequencing Kit and an ABI 3730xl
automated sequencer (Applied Biosystems, USA). Mutation anal-
yses were performed using Phred, Phrap, Consed, Polyphred 5.04
software (http://droog.mbt.washington.edu/PolyPhred.html).
2.3. Gene cloning
Coding sequence of the LGI1 gene with Xho I and EcoR I enzyme
sites was obtained from the LGI1 gene in the pBluescriptR vector
(Cat no. IRATp970G0723D, Image ID 4811956, Imagenes GmbH,
Germany) using PCR method (forward primer: 50-CCGCTCGAGGC-
CACCATGGAATCAGAAAGAAGC-30, reverse primer: 50-GGAATTCT-
CATGCGCTTAAGTCAAC-30), and inserted into the pcDNA3.1(-)
vector. After that, site-directed mutagenesis PCR was performed to
make the C46R and C46F mutagenized LGI1 clones (forward primer
for C46R: 50-CAAAATGCCCTGCCGTGCGTACTTGTACCAAAGAT-30,
reverse primer for C46R: 50-ATCTTTGGTACAAGTACGCACGG-
CAGGGCATTTTG-30, forward primer for C46F: 50-CCAAAATGCC-
CTGCCGTGTTTACTTGTACCAAAGATAAT-30, reverse primer for
C46F: 50- ATTATCTTTGGTATAAGTAAACACGGCAGGGCATTTTGG-
30, and these primers were PAGE puriﬁed).
2.4. Immunoblotting
Wild type, C46R, and C46F of LGI1 clone and pcDNA3.1(-) were
transfected into the Human Embryonic Kidney (HEK) 293T cells at
6-well plate using LipofectamineTM and PlusTM reagents (Cat no.
18324-020 and 10964-021, respectively, Invitrogen, USA), and the
transfecting solution was replaced with serum free media for
terminating transfection. 40 h after transfection, serum free media
was separately collected and centrifuged. The supernatant wascollected into the Amicon1 Ultra-4 3K Centrifugal Filters (Cat. no.
UFC800324, Millipore, USA) and centrifuged. The remaining
concentrated serum free media was added with 2 lysis buffer
(40 mM Tris, 300 mM NaCl, 20% Glycerol, 2% NP-40, and protease
inhibitor cocktail). Cell was washed twice with 1 phosphate
buffered saline and collected with rubber scraper at the 1 lysis
buffer (20 mM Tris, 150 mM NaCl, 10% Glycerol, 1% NP-40, and
protease inhibitor cocktail), then sonicated for 15 s. Cell lysate was
centrifuged and the supernatant was collected. 2 Tricine sample
buffer (Cat. no. KTR020, Koma Biotech Inc, Korea) was added to
the prepared media and cell lysate. EzWay PAG System Precast Gel
(4–12%) and Tricine running buffer (Cat. no. KG50105 and KTR030,
respectively, Koma Biotech Inc.) were used for gel electrophoresis.
Anti LGI1 (C-19) and Actin (I-19) antibodies (Cat. no. sc-9583 and
sc-1616, respectively, Santa Cruz, USA) were employed as primary
antibodies, and ImmunopureR antibody Rabbit anti-Goat IgG
(H + L) (Cat. no. 31402, Thermo Scientiﬁc, USA) was used as a
secondary antibody. Actin beta was used as a control for the cell
lysate.
2.5. In silico analysis
Model for leucine-rich repeat (LRR) domain of LGI1 was
calculated using automated modeling mode in the SWISS model
server (http://swissmodel.expasy.org/). Two crystal structures in
the LRR family of VLRB61 and Slit with four LRRs as template
models were adopted for modeling process. Model ﬁgures were
prepared using programs PyMol (DeLano Scientiﬁc). The amino
acid substituting effect for LGI1 protein stability was predicted
using the ‘Sorting Tolerant From Intolerant’ (SIFT) algorithm at the
online tool of http://sift.jcvi.org.11
3. Results
3.1. Clinical description
None of family members had the information for seizure history
of the ﬁrst generation. Among all family members, eleven
members experienced seizures: two of four in the second
generation, two of 17 in the third generation, six of 11 in the
fourth generation, and one of 19 in the ﬁfth generation (Fig. 1A).
None of them had antecedents for seizure. Three of the family
members were deceased (II-2, II-3, and III-12), and out of the eight
who were still alive, six (III-15, IV-8, IV-9, IV-14, IV-16, and IV-19)
were taking antiepileptic drugs (AEDs). The mean age at seizure
onset for the eight living members was 13.6 years (range, 10 to 22
years). The current mean age of unaffected (n = 8) offspring of the
affected fourth generation (IV-11, IV-14, and IV-16) is 13.1 years
(range, 7–18 years). All affected family members were right-
handed. The three deceased members had generalized tonic–clonic
seizures (GTCSs), and no living family member remembered the
characteristics of deceased members’ auras. All living affected
members had GTCSs. Patients IV-11 and V-9 had only one GTCS in
their lifetime. GTCSs occurred predominantly during sleep in four
members (III-15, IV-8, IV-16, and IV-19). Four members (III-15, IV-
9, IV-14, and IV-16) had complex partial seizures (CPSs). Two
members (III-15 and IV-14) described speciﬁc seizure precipitants
such as psychic stress, speech, and visual stimulus. The auras of
seven living members were as follows: simple or complex auditory
hallucinations (IV-8 and IV-9), vertiginous auras (IV-8, IV-16 and
IV-19), complex visual hallucinations (III-15), and psychic auras
(IV-14 and V-9). Six patients (III-15, IV-8, IV-9, IV-14, IV-16, and IV-
19) underwent routine scalp EEG recording with nasopharyngeal
electrodes. One patient (IV-16) showed synchronous bilateral
temporal sharp waves. Brain MRIs of ﬁve patients (III-15, IV-8,
IV-14, IV-16, and IV-19) revealed no signiﬁcant ﬁndings. Seizure
Fig. 1. Family pedigree and mutation. (A) Korean ADLTE family pedigree having LGI1 mutation of C46F. Circles denote females; squares denote males; deceased family
members are indicated with diagonal line; affected subjects are marked by black symbols; subjects with unknown information for seizure history are marked by gray
symbols. (B) Direct sequencing results of p.46 (c.137) are compared between wild type and mutant subject. (C) Immunoblotting assay of LGI1 wild type, C46R and F at the
HEK293T cell lysate and media. Beta actin was conﬁrmed for endogenous control. (D) LGI1 protein structures of wild type (WT) and C46F with disulﬁde bonds of cysteine rich
and LRR domains. The cysteine rich domain N-terminal to LRR, LRR, and cysteine-rich domain C-terminal to LRR are colored pink, yellow, and blue, respectively. Disulﬁde
bonds are indicated as orange lines.
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IV-9, IV-11, IV-16, IV-19, and V-9) had been seizure-free for 1
year before the time of the last follow-up. Patient IV-11 was never
treated with AED. Patient V-9 was treated with AEDs for three
years but was able to discontinue medication. Two patients (IV-8
and IV-14) receiving AEDs were still experiencing seizures. Clinical
proﬁles are summarized in Table 1.
3.2. Gene analysis
One nucleotide variant, c.137G > T was shared within the ﬁve
affected members, and this variant was not detected at theunaffected member and healthy controls. Each affected subject had
only one c.137G > T variant allele (Fig. 1B). All tested affected
members had heterozygote amino acid of p.C46F encoded by the
c.137G > T. which is located next to the c.136T > C coding p.C46R
known as rs104894166. C46R variant was already reported at the
members of Norwegian family.12
3.3. Protein secretion
Wild type LGI1 protein was detected in both cell lysate and
media. C46R and C46F mutation was only detected in the cell
lysate (Fig. 1C).
Table 1
Clinical proﬁles.
Subject Sex Age
(year)
Onset
(year)
F/U
(year)
Seizure MRI EEG AED (mg/day) Outcome
III-15 F 62 13 3 Complex visual hallucinations, CPS, GTCS N N PB 90 SF
Nocturnal predominance of GTCS
Precipitated by emotional stress, conversation, and staring water
IV-8 F 50 12 3 Simple and complex auditory hallucinations, GTCS N N VPA 500, LTG 200,
TPM 250
1 GTCS/month
Nocturnal predominance of GTCS 1 aura/week
IV-9 M 49 10 3 Simple auditory hallucinations, CPS, GTCS N/A N CBZ 200, PHT 200,
PB 60
SF
IV-11 M 46 22 GTCS N/A N/A Never treated SF
IV-14 F 43 14 3 Fear, CPS, GTCS N N VPA 1000, LTG 200,
TPM 50
1 CPS/month
Precipitated by concentration 1 aura/week
IV-16 F 41 13 3 Dizziness, CPS, GTCS N Bi-T SWs LTG 250 SF
Nocturnal predominance of GTCS
IV-19 M 37 15 3 Dizziness, GTCS N N CBZ 400 SF
Nocturnal predominance of GTCS
V-9 M 23 10 Fear, GTCS N/A N/A Previously treated SF
F, female; M, male; (year), years; F/U, follow-up periods; CPS, complex partial seizure; GTCS, generalized tonic–clonic seizure; N, normal; N/A, not available; Bi-T, bilateral
temporal; SWs, sharp waves; AED, antiepileptic drug; PB, phenobarbital; VPA, valproic acid; LTG, lamotrigine; TPM, topiramate; CBZ, carbamazepine; PHT, phenytoin; SF,
seizure-free for 1 year before the time of the last follow-up.
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There is a LRR domain at the center of the two cysteine rich
domains (Fig. 1D). Each cysteine rich domain has two disulﬁde
bonds composed of four cysteine residues. Of the two disulﬁde
bonds existed in the cysteine rich domain N-terminal to LRR, one is
located between the C42 and C48, and the other is between the C46
and C55. In the case of the C46F mutation, two disulﬁde bonds in
the cysteine rich domain C-terminal to LRR are declined to one.
LGI1 protein stability was predicted as ‘Tolerated’ or ‘Damaging’
according to the amino acid substitution for C46. All amino acids
substituted for cysteine were predicted as ‘Damaging’ status using
SIFT algorithm. Results of in silico analysis are shown in the on-line
supplementary data.
4. Discussion
The LGI1 protein has two main structural domains; four LRRs in
the N-terminal half, and seven epitempin (EPTP) repeats in the C-
terminal portion.13 Three LGI1 mutations affecting conserved
cysteine residue preceding LRR were reported to date.3,5,14
Disulﬁde bonds formed by cysteine residues play an important
role in maintaining structural stability by protecting the LRR
hydrophobic core from exposure.15 Although in silico analysis
using SIFT algorithm has a limitation for predicting the effect of
amino acid substitution that it does not use the protein structure,
all amino acids substituted at the C46 position impaired the
protein stability on SIFT prediction.11 Most epilepsy-associated
mutant LGI1 proteins were retained within the cell except for the
one encoded by the mutation (c.1219C > T).9 The C46F protein was
also retained within the cell in our experiment. These ﬁndings
reemphasize that conserved cysteine residue is a critical region for
normal protein function and a single functioning copy of LGI1 gene
is not enough for normal function, so that loss-of-function
mutations cause a dominant phenotype in this family.
The putative function of LGI1 protein is still unclear. The LGI1
protein has been found associated with different protein com-
plexes and several molecular mechanisms possibly underlying
ADLTE have been hypothesized. LGI1 forms membrane complexes
with Kv1.1 potassium channels. Both Kv1.1 and LGI1 are co-
assembled with KV1.4 and Kvbeta1. LGI1 selectively prevents
N-type inactivation mediated by the Kvbeta subunit. Changes in
inactivation gating of presynaptic Kv1.1 potassium channels maypromote epileptic activity.16 Extracellularly secreted LGI1 links
two epilepsy-related receptors, ADAM22 and ADAM23, in the brain
and organizes a transsynaptic protein complex that includes
presynaptic potassium channels and postsynaptic AMPA receptor
scaffolds. A lack of LGI1 disrupts this synaptic protein connection
and selectively reduces AMPA receptor-mediated synaptic trans-
mission.17 Also, LGI1 binding to ADAM23 is necessary to correctly
pattern neuronal morphology and altered anatomical patterning
contributes to ADLTE.18
Clinical ﬁndings were generally consistent with the character-
istics of ADLTE. Focal seizures are clinically characterized by
auditory auras in the majority of the cases. Other less frequent
auras include aphasic, visual, psychic, autonomic, vertiginous, and
other sensory symptoms.19 Two families with the C46R mutation
had prominent aphasic or auditory auras.12,14 The auras of our
patients appeared to be more diverse compared to the auras
induced by the C46R mutation. Five patients had psychic,
dizziness, and visual auras. Only two patients had auditory auras.
Ictal aphasia may not have been identiﬁed because of the lack of
prolonged EEG monitoring. Secondarily GTCSs are almost invari-
ably present in patients with ADLTE which is consistent with our
results.4 Seizures could be triggered by sounds, speech, or others
factors in ADLTE. One patient with visual auras described visual
stimuli as one of her seizure precipitants. The precipitating triggers
may reﬂect the natural function of epileptogenic focus in reﬂex
seizure. The progression of the condition is usually benign. Six of
eight living family members achieved seizure freedom. In the ﬁfth
generation (n = 11) whose parent had seizures, only one member
(V-9) experienced seizures. The paucity of seizure in the ﬁfth
generation may be explained by still low age for seizure onset or
incomplete penetrance (67% and 61.3%, respectively, in two
studies).6,20
5. Conclusions
A new LGI1 mutation was identiﬁed in a large Korean ADLTE
family. Sequencing of LGI1 revealed a heterozygous G to T
transversion at position 137 of the cDNA resulting in a missense
mutation in exon 1, which is predicted to substitute phenylalanine
for cysteine at position 46 of the LGI1 protein (C46F). Clinical and
genetic features were generally consistent with the previously
reported cases with the exception of the diversity of auras among
the affected family members. Further studies are required to
M.K. Lee et al. / Seizure 23 (2014) 69–73 73evaluate the phenotypic diversities of LGI1 mutation related
ADLTE.
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